Alzheimer’s Disease: Mechanism and Approach to Cell Therapy
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common form of dementia. The risk of AD increases with age. Although two of the main pathological features of AD, amyloid plaques and neurofibrillary tangles, were already recognized by Alois Alzheimer at the beginning of the 20th century, the pathogenesis of the disease remains unsettled. Therapeutic approaches targeting plaques or tangles have not yet resulted in satisfactory improvements in AD treatment. This may, in part, be due to early-onset and late-onset AD pathogenesis being underpinned by different mechanisms. Most animal models of AD are generated from gene mutations involved in early onset familial AD, accounting for only 1% of all cases, which may consequently complicate our understanding of AD mechanisms. In this article, the authors discuss the pathogenesis of AD according to the two main neuropathologies, including senescence-related mechanisms and possible treatments using stem cells, namely mesenchymal and neural stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992 · cited 1×
“An extracellular fragment of APP binds death receptor 6 (DR6) or p75NTR (DR6 has a much higher affinity for APP than does p75NTR) and triggers the degeneration of cell bodies [41].”
BackgroundRetractedAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“The former is targeted according to the amyloid cascade hypothesis [42–45], which is based on the deposition of Aβ protein, the main component of the plaques that drive AD, leading to NFTs, neuronal loss, vascular damage, and dementia [44].”
BackgroundMorris water maze: procedures for assessing spatial and related forms of learning and memory
Vorhees, C. V., & Williams, M. T. (2006) · Nature Protocols · doi:10.1038/nprot.2006.116 · Cited by 4,629
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 1×
“A large scale meta-analysis was performed using a genome-wide association study (GWAS), which revealed 22 associated genetic loci linked to SAD [23–25], Detailed descriptions of these genes have been published elsewhere [26–37].”
MethodOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“The 5xFAD animal model co-expresses human APP with the Swedish, Florida and London mutations and human PSEN1 with the M146L and L286V mutations and is known to show neuronal loss, but without NFTs [274].”
BackgroundKern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 1×
“[295–297].”
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“A large scale meta-analysis was performed using a genome-wide association study (GWAS), which revealed 22 associated genetic loci linked to SAD [23–25], Detailed descriptions of these genes have been published elsewhere [26–37].”
MethodNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“A large scale meta-analysis was performed using a genome-wide association study (GWAS), which revealed 22 associated genetic loci linked to SAD [23–25], Detailed descriptions of these genes have been published elsewhere [26–37].”
MethodAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“The former is targeted according to the amyloid cascade hypothesis [42–45], which is based on the deposition of Aβ protein, the main component of the plaques that drive AD, leading to NFTs, neuronal loss, vascular damage, and dementia [44].”
BackgroundLee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“Tau-based neurofibrillary pathology is found in more than 20 neurodegenerative diseases [68].”
BackgroundInflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 1×
“MSCs can produce prostaglandin E2, which modulates inflammatory reactions via the EP2 and EP4 receptors, and can reprogram macrophages to produce more IL-10 [309–311].”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Synaptic loss and microglial activation precede the onset of NFT formation, reflecting the impaired axonal transport that occurs as a result of Tau hyperphosphorylation [74,75].”
BackgroundCopper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 1×
“During AD progression, the expression of RAGE is upregulated in microglia, neurons and endothelial cells surrounding senile plaques [175].”
BackgroundInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 1×
“A large scale meta-analysis was performed using a genome-wide association study (GWAS), which revealed 22 associated genetic loci linked to SAD [23–25], Detailed descriptions of these genes have been published elsewhere [26–37].”
MethodNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“A large scale meta-analysis was performed using a genome-wide association study (GWAS), which revealed 22 associated genetic loci linked to SAD [23–25], Detailed descriptions of these genes have been published elsewhere [26–37].”
MethodDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 1×
“This altered Fyn localization may in turn activate Fyn via Aβ [149].”
BackgroundAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“Almost all aging organisms show a gradual decrease in UPS and autophagy activity [102].”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus
Cameron, H. A., & Mckay, R. D. G. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1040 · Cited by 1,585 · cited 1×
“, about 6% of total granule cells are generated in the DG each month), but most of these cells die between 1 and 2 weeks after birth [320].”
BackgroundInflammation is detrimental for neurogenesis in adult brain
Ekdahl, C. T., Claasen, J.-H., Bonde, S., Kokaia, Z., & Lindvall, O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2234031100 · Cited by 1,559
Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1836 · Cited by 1,513
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 13×
“Impaired glucose metabolism leads to decreased Tau O-GlcNAcylation and causes abnormal hyperphosphorylation of Tau, resulting in the NFTs observed in AD.”
BackgroundInfluentialPropagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“This was indicated in one study by the fact that Aβ vaccination almost entirely cleared Aβ, whilst the severe and progressive tangle pathology remained and clinical improvement was not achieved [81].”
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297 · cited 11×
“Senescence reinforces chronic inflammation including up-regulated TNF-α, IL-1β and IL-6, while oxidative stress is characterized by increased ROS [351], which are also involved in AD pathogenesis [352].”
BackgroundInfluentialCitron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 1×
“Mutation of the APP gene facilitates Aβ production whilst that of PSEN 1 and PSEN2 increases the production of Aβ42 via γ-secretase [13,14].”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“On the other hand, elevated levels of Aβ40 and Aβ42 correspond to the degree of cognitive decline when a single formic acid extract is used [47], suggesting that soluble Aβs, such as amyloid oligomers, correlate with disease severity [48].”
BackgroundProbing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253 · cited 15×
“Late-onset AD (LOAD) occurs after 65 years of age and is also known as sporadic AD (SAD), accounting for 85%–95% of AD cases [15].”
BackgroundInfluentialZiv, Y., Ron, N., Butovsky, O., Landa, G., Sudai, E., Greenberg, N., Cohen, H., Kipnis, J., & Schwartz, M. (2006) · Nature Neuroscience · doi:10.1038/nn1629 · Cited by 1,209 · cited 1×
“The former is characterized by the secretion of proinflammatory cytokines, including IL-1β, IL-6 and TNF-α, resulting in the impairment of neurogenesis [215,216], while the latter involves the production of GFs such as IGF-1, which stimulates neurogenesis [217].”
BackgroundThe neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118 · cited 1×
“However, amyloid plaque burden poorly correlates with disease severity [46].”
BackgroundA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“The results of a phase I trial suggested an improvement in cognitive decline [337].”
BackgroundTau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037 · cited 1×
“Downregulation of protein phosphatase-2A (PP2A), which regulates the activity of several Tau kinases and impairs brain glucose metabolism, contributes to abnormal hyperphosphorylation of Tau in AD [158].”
BackgroundNagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 1×
“BDNF is produced in the entorhinal cortex throughout life and is involved in neural plasticity [339].”
BackgroundAguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010 · cited 3×
“The pro-inflammatory cytokine TNF-α fosters serine phosphorylation of IRS-1 and IRS-2 via JNK binding with IRS proteins, inhibiting subsequent signaling pathways including PI3K/PKB and PI3K/Akt and leading to amyloid deposits and Tau hyperphosphorylation [202,203].”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 1×
“This animal model shows extracellular Aβ deposits in the frontal cortex at 6 months of age, spreading to the hippocampus by 12 months when Tau pathology appears in the hippocampus; however, no neuronal loss is observed [275,276].”
BackgroundPhosphorylation affects the ability of tau protein to promote microtubule assembly.
Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42989-9 · Cited by 901 · cited 2×
“Normal Tau interacts with tubulin, facilitates its assembly into microtubules and stabilizes their structure [66].”
BackgroundGene-targeting studies of mammalian behavior: is it the mutation or the background genotype?
Gerlai, R. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)20020-7 · Cited by 881
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 13×
“Impaired glucose metabolism leads to decreased Tau O-GlcNAcylation and causes abnormal hyperphosphorylation of Tau, resulting in the NFTs observed in AD.”
BackgroundInfluentialThe many faces of insulin-like peptide signalling in the brain
Fernandez, A. M., & Torres-Alemán, I. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3209 · Cited by 872 · cited 2×
“Insulin and IGF-1 can protect neurons against Aβ-induced synaptic toxicity [189,208].”
BackgroundInsulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782
O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775 · cited 1×
“In AD brains, the level of O-GlcNAcylation was 22% lower compared to controls [159].”
BackgroundMoloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
Cu(II) Potentiation of Alzheimer Aβ Neurotoxicity
Huang, X., Cuajungco, M. P., Atwood, C. S., Hartshorn, M. A., Tyndall, J. D. A., Hanson, G. R., Stokes, K. C., Leopold, M., Multhaup, G., Goldstein, L. E., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37111 · Cited by 762 · cited 1×
“Complexes of Aβ and Cu/Fe can generate ROS such as H2O2, leading to Aβ toxicity [170].”
BackgroundBrain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748 · cited 2×
“During aging, similar reductions occur for neuronal glucose metabolism, insulin levels and IR density [200].”
BackgroundTelomere length, stem cells and aging
Blasco, M. A. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.38 · Cited by 747 · cited 1×
“Telomere shortening is associated with increasing age to limit the proliferative capacity of stem cells [348].”
BackgroundInsulin signaling in health and disease
White, M. F. (2003) · Science · doi:10.1126/science.1092952 · Cited by 733 · cited 1×
“There are four members: IRS-1, IRS-2, IRS-3 and IRS-4 [192].”
BackgroundAPOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707 · cited 1×
“[20,21]; however, in sporadic cases its estimated prevalence risk is only 10%–20% [22].”
BackgroundAstrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., & Mahley, R. W. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90295-5 · Cited by 693 · cited 1×
“The majority of apolipoprotein E (APOE) is synthesized by the liver [265], but it is also partly produced by astrocytes [266] and microglia [267] in the brain.”
BackgroundAtwood, C. S., Scarpa, R. C., Huang, X., Moir, R. D., Jones, W. D., Fairlie, D. P., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751219.x · Cited by 641
Microglial dysfunction in brain aging and Alzheimer's disease
Mosher, K. I., & Wyss-Coray, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.008 · Cited by 618 · cited 1×
“Microglial clearance of Aβ appears to be dependent on age and also on the stage of the disease since Aβ is more effectively removed in the early stages of AD [241].”
BackgroundApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608
Jones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606 · cited 1×
“Cholesterol metabolism and immune response have been indicated as the primary causes of SAD among many categories used in one analysis [38].”
BackgroundNeocortical glial cell numbers in human brains
Pelvig, D. P., Pakkenberg, H., Stark, A. K., & Pakkenberg, B. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.013 · Cited by 601
Modeling familial Alzheimer's disease with induced pluripotent stem cells
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., & Suzuki, N. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr394 · Cited by 599
CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3158-09.2009 · Cited by 591 · cited 1×
“CD14 acts as a co-receptor for TLR2 and TLR4, and is required for microglial phagocytosis of Aβ [331].”
BackgroundAmyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587
Astrocyte Senescence as a Component of Alzheimer’s Disease
Bhat, R., Crowe, E. P., Bitto, A., Moh, M., Katsetos, C. D., Garcia, F. U., Johnson, F. B., Trojanowski, J. Q., Sell, C., & Torres, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045069 · Cited by 586 · cited 1×
“Although DNA damage in the hippocampal astrocytes of AD brains and an increased population of astrocytes from the frontal cortex of aged individuals and AD patients have been reported [272,273], further intensive studies are required to elucidate their causal relationship to AD pathogenesis and development and to use…”
BackgroundApolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 1×
“APOE has a receptor-binding site in its N-terminal domain and a lipid-binding site in its C-terminal domain [268].”
BackgroundBateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573
Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state
Lapasset, L., Milhavet, O., Prieur, A., Besnard, E., Babled, A., Aït-Hamou, N., Leschik, J., Pellestor, F., Ramirez, J.-M., De Vos, J., et al. (2011) · Genes & Development · doi:10.1101/gad.173922.111 · Cited by 570 · cited 1×
“Although they have been successfully generated from cells of a centenarian individual [343,344] and individuals with FAD [345] and SAD [346], they may reset the aging phenotype [347].”
BackgroundCD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · cited 1×
“In SAD, Tau-related pathologies are not believed to be downstream of Aβ pathologies, but rather amyloid and Tau pathologies may have dual independent pathways [79].”
BackgroundAging as an event of proteostasis collapse
Taylor, R. C., & Dillin, A. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004440 · Cited by 538 · cited 1×
“A functional decline in protein homeostasis (proteostasis) causes an accumulation of damaged and misfolded proteins in aging cells and diseases such as AD [88].”
BackgroundAdvanced glycation endproducts and their receptor RAGE in Alzheimer's disease
Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., & Münch, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.016 · Cited by 524 · cited 2×
“This binding also fosters ROS generation by activating NADPH oxidase (NOX), resulting in AD progression [177].”
BackgroundAlzheimer brain-derived tau oligomers propagate pathology from endogenous tau
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Kiritoshi, T., Neugebauer, V., Jackson, G. R., & Kayed, R. (2012) · Scientific Reports · doi:10.1038/srep00700 · Cited by 502
Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation
Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., Farhang-Fallah, J., Dikkes, P., Warot, X. M., Rio, C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-18-07084.2003 · Cited by 488
Koenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477
Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease
Masliah, E., Hansen, L., Alford, M., Deteresa, R., & Mallory, M. (1996) · Annals of Neurology · doi:10.1002/ana.410400512 · Cited by 476
Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911829107 · Cited by 466 · cited 1×
“Ablation or overexpression of PrPC had no effect on hippocampal synaptic plasticity and oligomer-induced cognitive impairment [137,138].”
BackgroundLauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R., & Butterfield, D. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00451.x · Cited by 464 · cited 1×
“This process is facilitated by excessive Aβ42 and leads to the inhibition of glutamate transport and increased extraneuronal glutamate accumulation that consequently results in cell death [255].”
BackgroundOxidative stress in Alzheimer disease
Gella, A., & Durany, N. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.1.7402 · Cited by 459
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459 · cited 1×
“Calpain activation leading to p25 accumulation and elevated Cdk5 activity has been found in the AD brain [146].”
BackgroundProteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
Liu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., & Gong, C.-X. (2009) · Brain · doi:10.1093/brain/awp099 · Cited by 439 · cited 3×
“However, this consumption of glucose decreases with age and in AD [151].”
BackgroundIncreased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
GERAD consortium, Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K. V., Geller, F., Sottejeau, Y., Harold, D., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.1 · Cited by 407 · cited 1×
“A large scale meta-analysis was performed using a genome-wide association study (GWAS), which revealed 22 associated genetic loci linked to SAD [23–25], Detailed descriptions of these genes have been published elsewhere [26–37].”
MethodSlooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Van Broeckhoven, C., & van Duijn, C. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.964 · Cited by 399 · cited 1×
“[20,21]; however, in sporadic cases its estimated prevalence risk is only 10%–20% [22].”
BackgroundButovsky, O., Koronyo-Hamaoui, M., Kunis, G., Ophir, E., Landa, G., Cohen, H., & Schwartz, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604681103 · Cited by 388
Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381
Lucin, K. M., O’Brien, C. E., Bieri, G., Czirr, E., Mosher, K. I., Abbey, R. J., Mastroeni, D. F., Rogers, J., Spencer, B., Masliah, E., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.046 · Cited by 374 · cited 1×
“Furthermore, the levels of beclin 1 and retromer protein are significantly reduced in microglia isolated from human AD brains, which may lead to an insufficient microglial phagocytic capacity to clear Aβ [242].”
BackgroundPhase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · cited 1×
“Repeated treatment with solanezumab did not show a significant benefit in data obtained from patients with mild or moderate AD dementia, but a slowing of cognitive decline was found in approximately 34% of mild AD patients, diagnosed as ADAS-Cog14 (AD Assessment Scale Cognitive subscale) [60,62,63], supporting the sug…”
BackgroundDoens, D., & Fernández, P. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-48 · Cited by 348 · cited 3×
“One is mediated by several receptors that are expressed in microglia, including scavenger receptors (SR), formyl peptide-receptor-like 1 (FPRL1), complement receptors, FcRs, and TREM2 [236].”
BackgroundBrain oxidative stress in a triple-transgenic mouse model of Alzheimer disease
Resende, R., Moreira, P. I., Proença, T., Deshpande, A., Busciglio, J., Pereira, C., & Oliveira, C. R. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.012 · Cited by 343
Intraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease
Gouras, G. K., Almeida, C. G., & Takahashi, R. H. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.022 · Cited by 338 · cited 1×
“Oskar Fischer also found and described neurite plaques in senile dementia cases in the same year [2].”
BackgroundHow does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
Zhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., Frautschy, S. A., & Cole, G. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2860-04.2004 · Cited by 329
Expression of Novel Alzheimer’s Disease Risk Genes in Control and Alzheimer’s Disease Brains
Karch, C. M., Jeng, A. T., Nowotny, P., Cady, J., Cruchaga, C., & Goate, A. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050976 · Cited by 328
mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging
Frank, M. G., Barrientos, R. M., Biedenkapp, J. C., Rudy, J. W., Watkins, L. R., & Maier, S. F. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.013 · Cited by 327
Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · cited 1×
“Passive immunization trials have shown that Tau related pathology could be reduced when the antibody was administered at early time points prior to the onset of Tau pathology [83,84].”
BackgroundCho, S.-H., Sun, B., Zhou, Y., Kauppinen, T. M., Halabisky, B., Wes, P., Ransohoff, R. M., & Gan, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.254268 · Cited by 268 · cited 1×
“The level of plasma soluble CX3CL1 was markedly higher in patients with mild to moderate AD than in those with severe AD [225], and the level of tissue CX3CL1 was lower in the hippocampus and the frontal cortex of AD patients [226].”
BackgroundEpigenetic regulation in the pathophysiology of Alzheimer's disease
Chouliaras, L., Rutten, B. P. F., Kenis, G., Peerbooms, O., Visser, P. J., Verhey, F., van Os, J., Steinbusch, H. W. M., & van den Hove, D. L. A. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.002 · Cited by 262 · cited 1×
“Their aging includes oxidative stress, chronic inflammation, calcium dyshomeostasis, chromosomal instability and nuclear and mitochondrial DNA damage [287].”
BackgroundLyons, A., Downer, E. J., Crotty, S., Nolan, Y. M., Mills, K. H. G., & Lynch, M. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1781-07.2007 · Cited by 258 · cited 1×
“CD200R is an inhibitory receptor on microglia, which are maintained in a quiescent state by the interaction between CD200R and CD200, a transmembrane glycoprotein expressed on neurons [227].”
BackgroundVelliquette, R. A., O'Connor, T., & Vassar, R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2350-05.2005 · Cited by 254
Prion protein and Aβ‐related synaptic toxicity impairment
Calella, A. M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I. M., & Aguzzi, A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000082 · Cited by 242
What are lipoproteins doing in the brain?
Wang, H., & Eckel, R. H. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.003 · Cited by 234 · cited 1×
“Since the blood brain barrier (BBB) prevents the uptake of lipoproteins, brain cholesterol must be derived from de novo synthesis [110].”
BackgroundAkt and CHIP coregulate tau degradation through coordinated interactions
Dickey, C. A., Koren, J., Zhang, Y.-J., Xu, Y.-F., Jinwal, U. K., Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709180105 · Cited by 226
Neurotoxic protein oligomers — what you see is not always what you get
Bitan, G., Fradinger, E. A., Spring, S. M., & Teplow, D. B. (2005) · Amyloid · doi:10.1080/13506120500106958 · Cited by 221 · cited 2×
“NMDAR phosphorylation in turn causes LTP inhibition, oxidative stress, apoptosis and calcium dysregulation, resulting in neuronal loss and memory impairment [51,132,133].”
BackgroundLyons, A., Lynch, A. M., Downer, E. J., Hanley, R., O’Sullivan, J. B., Smith, A., & Lynch, M. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06253.x · Cited by 202
Basak, J. M., Verghese, P. B., Yoon, H., Kim, J., & Holtzman, D. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.288746 · Cited by 198
Miyashita, A., Koike, A., Jun, G., Wang, L.-S., Takahashi, S., Matsubara, E., Kawarabayashi, T., Shoji, M., Tomita, N., Arai, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058618 · Cited by 196
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
mTOR‐dependent signalling in Alzheimer's disease
Pei, J., & Hugon, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00509.x · Cited by 190
Lee, J. K., Jin, H. K., & Bae, J.-S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.059 · Cited by 189 · cited 1×
“IL-6, when stimulated with Aβ [305].”
Deregulated Cdk5 activity is involved in inducing Alzheimer's disease
Shukla, V., Skuntz, S., & Pant, H. C. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.015 · Cited by 185 · cited 1×
“Through its p10 myristoylated N-terminal end, p35 is bound to the membrane, while in contrast p25 localizes to the cell soma because of its lack of p10 [145].”
BackgroundZou, J., Wang, Y.-X., Dou, F.-F., Lü, H.-Z., Ma, Z.-W., Lu, P.-H., & Xu, X.-M. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2009.12.021 · Cited by 181
Telomere Shortening in Neural Stem Cells Disrupts Neuronal Differentiation and Neuritogenesis
Ferrón, S. R., Marqués-Torrejón, M. Á., Mira, H., Flores, I., Taylor, K., Blasco, M. A., & Fariñas, I. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3836-09.2009 · Cited by 179
Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein
Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease
Selfridge, J. E., E, L., Lu, J., & Swerdlow, R. H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.057 · Cited by 175
Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes
Myung, N.-H., Zhu, X., Kruman, I. I., Castellani, R. J., Petersen, R. B., Siedlak, S. L., Perry, G., Smith, M. A., & Lee, H.-G. (2008) · AGE · doi:10.1007/s11357-008-9050-7 · Cited by 170
The emerging role of glutathione in Alzheimer’s disease
Saharan, S., & Mandal, P. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132483 · Cited by 168 · cited 1×
“Levels of glutathione decrease with age [163] and in AD [164].”
BackgroundBrain cholesterol in normal and pathological aging
Martin, M., Dotti, C. G., & Ledesma, M. D. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.03.011 · Cited by 162 · cited 1×
“The human brain contains about 25% of the body’s total cholesterol [109].”
BackgroundKulijewicz‐Nawrot, M., Verkhratsky, A., Chvátal, A., Syková, E., & Rodríguez, J. J. (2012) · Journal of Anatomy · doi:10.1111/j.1469-7580.2012.01536.x · Cited by 160 · cited 1×
“An age-dependent decrease in GS-positive astrocytes was reported in the hippocampus of 3xTg-AD mice, and GS expression in astrocytes was reduced in the medial prefrontal cortex of the same transgenic mice by the age of 12 months compared with age-matched controls [259,260].”
BackgroundInsulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ
Zhao, W.-Q., Lacor, P. N., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011015 · Cited by 154
Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity
Limatola, C., Lauro, C., Catalano, M., Ciotti, M. T., Bertollini, C., Di Angelantonio, S., Ragozzino, D., & Eusebi, F. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.03.023 · Cited by 153 · cited 1×
“CX3CL1 also protects against excitotoxicity leading to neuronal death through the activation of the ERK1/2 and PI3K/Akt pathways [223,224].”
BackgroundLinking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress
Manolopoulos, K. N., Klotz, L.-O., Korsten, P., Bornstein, S. R., & Barthel, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.17 · Cited by 150
Rohn, T. T., Vyas, V., Hernandez-Estrada, T., Nichol, K. E., Christie, L.-A., & Head, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5620-07.2008 · Cited by 146
Oskar Fischer and the study of dementia
Goedert, M. (2008) · Brain · doi:10.1093/brain/awn256 · Cited by 144
Oxidative modification of lipoic acid by HNE in Alzheimer disease brain
Hardas, S. S., Sultana, R., Clark, A. M., Beckett, T. L., Szweda, L. I., Murphy, M. P., & Butterfield, D. A. (2013) · Redox Biology · doi:10.1016/j.redox.2013.01.002 · Cited by 120 · cited 1×
“Lipid peroxidation induced by Aβ oligomers in the lipid layer fosters lipid peroxidation products including 4-hydroxy-2-nonenal (HNE), malondialdehyde, F2-isoprostanes, and 2-propyn-1-ol [184].”
BackgroundAmyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity
Nicoll, A. J., Panico, S., Freir, D. B., Wright, D., Terry, C., Risse, E., Herron, C. E., O’Malley, T., Wadsworth, J. D. F., Farrow, M. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3416 · Cited by 119 · cited 1×
“Recent studies suggest that these conflicting results may be attributed to differences in soluble Aβ, the location of its binding site in PrPC and/or the animal models used [139,140].”
ResultHernandez, P., Lee, G., Sjoberg, M., & Maccioni, R. B. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0933 · Cited by 107
Golde, T. E., & Miller, V. M. (2009) · Alzheimer's Research & Therapy · doi:10.1186/alzrt5 · Cited by 98 · cited 7×
“Senescence reinforces chronic inflammation including up-regulated TNF-α, IL-1β and IL-6, while oxidative stress is characterized by increased ROS [351], which are also involved in AD pathogenesis [352].”
BackgroundInfluentialKinase activities increase during the development of tauopathy in htau mice
Kelleher, I., Garwood, C., Hanger, D. P., Anderton, B. H., & Noble, W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04930.x · Cited by 78
Microglia as a critical player in both developmental and late-life CNS pathologies
Derecki, N. C., Katzmarski, N., Kipnis, J., & Meyer-Luehmann, M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1321-z · Cited by 78
Cacquevel, M., Aeschbach, L., Houacine, J., & Fraering, P. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035133 · Cited by 75
MyD88 Deficiency Ameliorates β-Amyloidosis in an Animal Model of Alzheimer's Disease
Lim, J.-E., Kou, J., Song, M., Pattanayak, A., Jin, J., Lalonde, R., & Fukuchi, K.-I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.045 · Cited by 63
Cited by
Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O. R., Hamidi, G. A., & Salami, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00256 · Cited by 946
“AD begins with memory loss of recent events (short-term memory impairment) and finally robs the patients of their sense of self (Amemori et al., 2015).”
BackgroundFunctional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases
Lo Furno, D., Mannino, G., & Giuffrida, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26192 · Cited by 177
The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer’s Disease
Ogunmokun, G., Dewanjee, S., Chakraborty, P., Valupadas, C., Chaudhary, A., Kolli, V., Anand, U., Vallamkondu, J., Goel, P., Paluru, H. P. R., et al. (2021) · Cells · doi:10.3390/cells10102790 · Cited by 85
Metadata
- Authors
- Amemori, T., Jendelova, P., Ruzicka, J., Urdzikova, L., & Sykova, E.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-11-04
- Volume
- 16
- Issue
- 11
- Pages
- 26417-26451
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W1901837091
- Cited by
- 102
- References
- 137
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.